Severity, treatment and follow-up of immune checkpoint inhibitor-related pneumonitis (ICI-P) in series
| First author [ref.] | Subjects n | ICI-P n | Grade | Cancer response | ICI treatment | Corticosteroids | Antibiotics | ICI-P evolution | Other treatments |
| Naidoo [76] | 915 | 43 60% ipilimumab# | Grade 1–2: 71% Grade ≥3: 29% Grade 5: 2.3% | CR+PR 61% SD 34% PD 5% | Pursued 48% Suspended 28% Stopped 24% | 51.6% 50 (20–80) mg 68 (20–154) days | ND | Resolved 74.4% Improved 11.6% Worsened 11.6% | Yes Infliximab or CPM (n=5) |
| Delaunay [80] | 1828 | 64 | Grade 1–2: 55% Grade ≥3: 45% Grade 5: 17% | CR+PR 36% SD 33% PD 11% Not known 20% | Pursued 8% Suspended 17% Stopped 75% | 86.9% 80 (20–240) mg 27 (4–251) days | 66.1% | Resolved 28.6% Improved 39.7% Stable 20.6% | No |
| Kato [78] | 111 | 8 | Grade 1–2: 75% Grade ≥3: 25% Grade 5: 13% | ND | ND | 87.5% ND ND | ND | Resolved 87.5 | Yes CPM (n=1) |
| Suresh [77] | 205 | 39 | Grade 1–2: 36% Grade ≥3: 64% Grade 5: 13% | ND | ND | 100% 1 mg·kg−1 per day ND | ND | Resolved 5.1% Improved 64% Worsened 17.9% | Yes 2/2 MMF improved 2/3 infliximab improved |
| Cho [79] | 167 | 22 | Grade 1–2: 68% Grade ≥3: 32% Grade 5: 18% | CR+PR 23% SD 45% PD 32% | Pursued 5% Suspended 32% Stopped 63% | 77% 0.8 (0.4–11.7) mg·kg−1 27 (2–269) days | 59% | Resolved 22.7% Improved 27.3% Stable 4.5% | No |
CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; ND: not done; CPM: cyclophosphamide; MMF: mycophenolate mofetil. #: in this study, 60% of subjects were melanoma patients treated using ipilimumab.